1. Home
  2. MYFW vs IPHA Comparison

MYFW vs IPHA Comparison

Compare MYFW & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MYFW

First Western Financial Inc.

N/A

Current Price

$30.50

Market Cap

312.1M

Sector

Finance

ML Signal

N/A

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$1.87

Market Cap

165.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MYFW
IPHA
Founded
2002
1999
Country
United States
France
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
312.1M
165.3M
IPO Year
2018
2014

Fundamental Metrics

Financial Performance
Metric
MYFW
IPHA
Price
$30.50
$1.87
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
$27.00
$5.75
AVG Volume (30 Days)
37.7K
20.2K
Earning Date
04-23-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
54.02
N/A
EPS
1.20
N/A
Revenue
$96,914,000.00
N/A
Revenue This Year
$20.48
$180.36
Revenue Next Year
$9.70
N/A
P/E Ratio
$25.63
N/A
Revenue Growth
7.60
N/A
52 Week Low
$21.96
$1.18
52 Week High
$34.36
$2.71

Technical Indicators

Market Signals
Indicator
MYFW
IPHA
Relative Strength Index (RSI) 44.48 39.91
Support Level $30.08 $1.66
Resistance Level $31.24 $1.94
Average True Range (ATR) 0.74 0.08
MACD 0.00 -0.05
Stochastic Oscillator 19.77 9.86

Price Performance

Historical Comparison
MYFW
IPHA

About MYFW First Western Financial Inc.

First Western Financial Inc is a financial holding company that provides a fully integrated suite of wealth management services on its private trust bank platform, which includes a comprehensive selection of deposit, loan, trust, wealth planning, and investment management products and services. The company has two operating segments; The Wealth Management segment consists of operations relative to the Company's fully integrated wealth management products and services, and The Mortgage segment consists of operations relative to the Company's residential mortgage service offerings. The bank derives its majority revenue from the wealth management segment.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: